肝细胞癌的新型治疗方法
Novel Therapies for Hepatocellular Carcinoma.
作者信息
Rimassa Lorenza
机构信息
Medical Oncology and Hematology Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center-IRCCS, 20089 Rozzano (Milan), Italy.
Department of Biomedical Sciences, Humanitas University, 20090 Pieve Emanuele (Milan), Italy.
出版信息
Cancers (Basel). 2020 Oct 20;12(10):3049. doi: 10.3390/cancers12103049.
Abstract
Since 2007, for patients with advanced- or intermediate-stage hepatocellular carcinoma (HCC) unsuitable for locoregional treatments and with preserved liver function, the multikinase inhibitor (MKI) sorafenib has been the worldwide standard of care [...].
摘要
自2007年以来，对于不适合局部区域治疗且肝功能良好的晚期或中期肝细胞癌（HCC）患者，多激酶抑制剂（MKI）索拉非尼一直是全球的标准治疗药物[……]
相似文献
1
Novel Therapies for Hepatocellular Carcinoma.肝细胞癌的新型治疗方法
Cancers (Basel). 2020 Oct 20;12(10):3049. doi: 10.3390/cancers12103049.
2
Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.钇-90微球放射性栓塞治疗不可切除的肝细胞癌
Cochrane Database Syst Rev. 2016 Feb 16;2:CD011313. doi: 10.1002/14651858.CD011313.pub2.
3
Treatment algorithm for intermediate and advanced stage hepatocellular carcinoma: Korea.中晚期肝细胞癌治疗算法：韩国。
Oncology. 2011;81 Suppl 1:141-7. doi: 10.1159/000333277. Epub 2011 Dec 22.
4
Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved?临床中晚期肝细胞癌的治疗：如何改善疗效？
Oncologist. 2010;15 Suppl 4:42-52. doi: 10.1634/theoncologist.2010-S4-42.
5
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma and future treatments for the poor responders.经肝动脉灌注化疗治疗晚期肝细胞癌及对无应答者的未来治疗方法。
Hepatol Res. 2012 Apr;42(4):340-8. doi: 10.1111/j.1872-034X.2011.00938.x. Epub 2011 Dec 13.
6
Evolving role of Sorafenib in the management of hepatocellular carcinoma.索拉非尼在肝细胞癌治疗中的角色演变
World J Clin Oncol. 2017 Jun 10;8(3):203-213. doi: 10.5306/wjco.v8.i3.203.
7
Role of Systemic Therapy and Future Directions for Hepatocellular Carcinoma.全身治疗在肝细胞癌中的作用及未来方向
Cancer Control. 2017 Jul-Sep;24(3):1073274817729243. doi: 10.1177/1073274817729243.
8
Sorafenib for the treatment of advanced hepatocellular carcinoma.索拉非尼治疗晚期肝细胞癌。
Health Technol Assess. 2010 May;14 Suppl 1:17-21. doi: 10.3310/hta14Suppl1/03.
9
Progress in surgical and nonsurgical approaches for hepatocellular carcinoma treatment.肝细胞癌治疗的手术及非手术方法进展
Hepatobiliary Pancreat Dis Int. 2016 Jun;15(3):234-56. doi: 10.1016/s1499-3872(16)60097-8.
10
Hepatocellular carcinoma: recent advances and emerging medical therapies.肝细胞癌：最新进展与新兴医学疗法
F1000Res. 2020 Jun 17;9. doi: 10.12688/f1000research.24543.1. eCollection 2020.
引用本文的文献
1
Modeling Hepatocellular Carcinoma Cells Dynamics by Serological and Imaging Biomarkers to Explain the Different Responses to Sorafenib and Regorafenib.通过血清学和影像学生物标志物对肝细胞癌细胞动力学进行建模，以解释对索拉非尼和瑞戈非尼的不同反应。
Cancers (Basel). 2021 Apr 25;13(9):2064. doi: 10.3390/cancers13092064.
本文引用的文献
1
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial.纳武利尤单抗联合伊匹木单抗治疗索拉非尼治疗后晚期肝细胞癌患者的疗效和安全性：CheckMate 040 随机临床试验。
JAMA Oncol. 2020 Nov 1;6(11):e204564. doi: 10.1001/jamaoncol.2020.4564. Epub 2020 Nov 12.
2
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma.仑伐替尼联合帕博利珠单抗治疗不可切除肝细胞癌的 Ib 期研究。
J Clin Oncol. 2020 Sep 10;38(26):2960-2970. doi: 10.1200/JCO.20.00808. Epub 2020 Jul 27.
3
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.阿替利珠单抗联合或不联合贝伐珠单抗治疗不可切除肝细胞癌（GO30140）：一项开放标签、多中心、1b 期研究。
Lancet Oncol. 2020 Jun;21(6):808-820. doi: 10.1016/S1470-2045(20)30156-X.
4
Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design.卡博替尼联合阿替利珠单抗与索拉非尼用于初治晚期肝细胞癌的比较：COSMIC-312 期研究设计。
Future Oncol. 2020 Jul;16(21):1525-1536. doi: 10.2217/fon-2020-0283. Epub 2020 Jun 3.
5
Navigating the new landscape of second-line treatment in advanced hepatocellular carcinoma.探索晚期肝细胞癌二线治疗的新领域。
Liver Int. 2020 Aug;40(8):1800-1811. doi: 10.1111/liv.14533. Epub 2020 Jun 10.
6
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌。
N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.
7
Which choice of therapy when many are available? Current systemic therapies for advanced hepatocellular carcinoma.当有多种疗法可供选择时，该如何抉择？晚期肝细胞癌的当前全身治疗方法。
Health Sci Rep. 2020 Jan 29;3(1):e147. doi: 10.1002/hsr2.147. eCollection 2020 Mar.
8
Molecular therapies for HCC: Looking outside the box.肝细胞癌的分子疗法：跳出框框思考。
J Hepatol. 2020 Feb;72(2):342-352. doi: 10.1016/j.jhep.2019.09.010.
9
Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma.免疫检查点抑制剂联合治疗肝细胞癌的挑战。
J Hepatol. 2020 Feb;72(2):307-319. doi: 10.1016/j.jhep.2019.09.025.
10
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial.帕博利珠单抗作为 KEYNOTE-240 中晚期肝细胞癌二线治疗的疗效：一项随机、双盲、III 期试验。
J Clin Oncol. 2020 Jan 20;38(3):193-202. doi: 10.1200/JCO.19.01307. Epub 2019 Dec 2.
Zotero 插件